Latigo Biotherapeutics Aims for $247 Million IPO

Latigo Biotherapeutics seeks a large investment. The company aims for a $247 million initial public offering, an IPO. This money will help fund its new pain drugs.

Latigo is working on non-opioid pain relief. These drugs could offer a safer choice for patients. Opioids carry risks like addiction.

Vertex Pharmaceuticals also develops a similar drug. Latigo's work could provide a needed alternative. This is good news for people living with pain.

The company's plans show a strong step forward. They bring new hope for better pain treatment. Investors watch closely as Latigo prepares for its IPO.

Source: FierceBiotech